Skip to main content

Andrew John Armstrong

Professor of Medicine
Medicine, Medical Oncology
Duke Box 103861, Durham, NC 27710
GSRB1 Room 3006, 905 La Salle St, Durham, NC 27710

Selected Grants


BMS CA125-1008: AR degradation in mCRPC patients

Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2024 - 2029

PRESERVE-006: ONC-392 plus Pluvicto in ARTA resistant mCRPC

Clinical TrialPrincipal Investigator · Awarded by OncoC4 · 2024 - 2028

Inhibiting Rev1-mediated DNA translesion synthesis for cancer therapy

ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2028

The Duke Preparing Research scholars In bioMEdical sciences (PRIME): Cancer Research Program

ResearchPreceptor · Awarded by National Institutes of Health · 2023 - 2028

Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate Cancer

ResearchCollaborator · Awarded by National Institutes of Health · 2022 - 2027

BMS CA125-1008: AR degradation in mCRPC patients

Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2024 - 2029

PRESERVE-006: ONC-392 plus Pluvicto in ARTA resistant mCRPC

Clinical TrialPrincipal Investigator · Awarded by OncoC4 · 2024 - 2028

Inhibiting Rev1-mediated DNA translesion synthesis for cancer therapy

ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2028

The Duke Preparing Research scholars In bioMEdical sciences (PRIME): Cancer Research Program

ResearchPreceptor · Awarded by National Institutes of Health · 2023 - 2028

Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate Cancer

ResearchCollaborator · Awarded by National Institutes of Health · 2022 - 2027

DoD: PCRP Clinical Consortium: Duke University Clinical Research Site

ResearchPrincipal Investigator · Awarded by Department of Defense · 2007 - 2026

Defining clinically actionable subtypes of castration-resistant prostate cancer through epigenetic cell-free DNA analysis

ResearchCo Investigator · Awarded by Dana-Farber Cancer Institute · 2023 - 2026

Blocking glutamine utilization in advanced and therapy-resistant prostate cancer

ResearchCo-Mentor · Awarded by Department of Defense · 2024 - 2026

Validation of predictive liquid biomarkers for patients with metastatic prostate cancer

ResearchPrincipal Investigator · Awarded by University of Wisconsin - Madison · 2023 - 2026

DAROL: Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients

ResearchPrincipal Investigator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2021 - 2026

Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2020 - 2025

Targeting neuroendocrine cells in prostate cancer with small molecule and targeted radionuclide therapies

ResearchPrincipal Investigator · Awarded by Prostate Cancer Foundation · 2023 - 2025

Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2025

Interrupting the aberrant cancer development sequence in epithelial cancer progression

ResearchMentor · Awarded by Prostate Cancer Foundation · 2021 - 2025

Therapeutic Targeting of The Long Noncoding RNA SCHLAP1 in Aggressive Prostate Cancer

ResearchCo Investigator · Awarded by National Institutes of Health · 2023 - 2024

PSMAi-PARPi combination agents for the targeted Auger and alpha therapy of metastatic castration-resistant prostate cancer

ResearchCo Investigator · Awarded by National Institutes of Health · 2022 - 2024

Exploiting Ferroptosis for the Treatment of RB1-Deficient Lethal Prostate Cancer

ResearchCo-Mentor · Awarded by Department of Defense · 2022 - 2024

HOXB13 as a therapeutic target in prostate cancer

ResearchCo Investigator · Awarded by Prostate Cancer Foundation · 2020 - 2024

Targeting Convergent Mechanisms of Therapy Resistance, Metastasis, and Immune Evasion with CBP inhibitors

ResearchCo Investigator · Awarded by FORMA Therapeutics, Inc. · 2020 - 2022

PROPHECY CTC PSMA Project

ResearchCollaborator · Awarded by Epic Sciences, Inc · 2022 - 2022

Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer

ResearchPrincipal Investigator · Awarded by Department of Defense · 2018 - 2022

Targeting the p38/Snail/PD-L1 axis in hormone-therapy resistance and metastasis

ResearchCo Investigator · Awarded by Department of Defense · 2018 - 2022

Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer

ResearchPartnering PI · Awarded by Department of Defense · 2018 - 2022

Defining the Relevant Immune Checkpoints Expressed on Metastatic Prostate Cancer Circulating Tumor Cells

ResearchPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2016 - 2021

STREAM - Salvage Therapeutic Radiation with Enzalutamide and ADT in Men with Recurrent Prostate Cancer

Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2014 - 2020

Pharmacology Industry Internships for Ph.D. Students

Inst. Training Prgm or CMEParticipating Faculty Member · Awarded by American Society for Pharmacology and Experimental Therapeutics · 2017 - 2019

Pharmacodynamic Study of Radium-223 in Men with Bone Metastatic Castration-Resistant Prostate Cancer (CRPC)

Clinical TrialPrincipal Investigator · Awarded by Bayer Corporation · 2014 - 2019

A Phase 2 Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients with Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Clinical TrialPrincipal Investigator · Awarded by Weill Medical College of Cornell University · 2013 - 2019

Testing the efficacy of AR degrading compounds in enzalutamide-resistant prostate cancer

ResearchInvestigator · Awarded by Arvinas Inc. · 2017 - 2019

AR variant regulation during EMT and disease progression

FellowshipPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2018

Developing and Validating Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate Cancer

ResearchCo Investigator · Awarded by National Institutes of Health · 2011 - 2016

Alternative splicing and epithelial-mesenchymal plasticity in prostate tumors

ResearchCollaborating Investigator · Awarded by National Institutes of Health · 2008 - 2014

External Relationships


  • Astellas Pharma Inc.
  • AstraZeneca
  • Bayer
  • Bill Albrecht
  • Bristol-Myers Squibb
  • Astellas Pharma Inc.
  • AstraZeneca
  • Bayer
  • Bill Albrecht
  • Bristol-Myers Squibb
  • Clearview Health Partners
  • Clinical Advances in Hematology Oncology
  • Epic Sciences
  • Expert Connect
  • Global Guidepoint
  • GoodRx
  • Ideaya Biosciences
  • Janssen Pharmaceuticals (Johnson & Johnson)
  • MJH Life Sciences
  • Merck Sharpe & Dohme (Merck & Co, USA)
  • Myovant Sciences, Inc
  • Neil Love CME
  • OncLive
  • Pfizer Inc.
  • WebMD/Medscape

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.